Entremed (ENMD) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-6.78M
Depreciation and amortization
Write-off of in-process R&D
Stock-based compensation expense	2.2M
Gain on sale of assets	-12.46K
Realized gain on sale of short-term investment
Non-cash interest	21.02K
Investment impairment loss
Accounts receivable	0
Prepaid expenses and other	40.84K
Accounts payable	34.79K
Accrued liabilities	-7.49K
Net cash used in operating activities
Proceeds from sale of assets
Proceeds from sale of short-term investment
Purchases of furniture and equipment	-159.24K
Net cash provided (used in) by investing activities
Stock issuance costs	-72.09K
Repayment of loan
Net proceeds from common stock subscribed	17.25M
Net proceeds from sale of common stock or exercise of options and warrants
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents	19.01M
Cash and cash equivalents at beginning of period	5.13M
Cash and cash equivalents at end of period	24.14M
Cash paid during the period for interest
Stock issued in connection with milestone payment related to acquisition of Miikana

Entities mentioned with ENMD

View All Entities